Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs

Xiaowei Yang, Jingjing Zhu, Chun Yu Tung, Gail Gardiner, Qun Wang, Hua Chen Chang, Baohua Zhou

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and mediator production in macrophages. In this study we demonstrate that lunasin can effectively suppress allergic airway inflammation in two murine models of asthma. In an OVA +Alum sensitization model, intranasal lunasin treatment at the time of OVA challenges significantly reduced total cells counts in bronchoalveolar lavage (BAL) fluid and eosinophilia, peribronchiolar inflammatory infiltration, goblet cell metaplasia and airway IL-4 production. In an OVA+LPS intranasal sensitization model, lunasin treatment either at the time of sensitization or challenge has similar effects in suppress allergic airway inflammation including significantly reduced total cell and eosinophil counts in BAL fluid, inflammatory gene Fizz1 expression in the lung, and IL-4 production by OVA re-stimulated cells from mediastinal lymph nodes. We further show that intranasal instillation of OVA+lunasin significantly increases OVA-specific regulatory T cell (Treg) accumulation in the lung comparing to OVA only treatment. Taken together, our results suggest lunasin as an anti-inflammatory agent can be potentially used in asthma therapy or as an adjuvant to enhance the induction of antigen-specific Tregs and thus boost the efficacy of allergy immunotherapy.

Original languageEnglish
Article numbere0115330
JournalPLoS One
Volume10
Issue number2
DOIs
StatePublished - Feb 3 2015

Fingerprint

inflammation
asthma
interleukin-4
Inflammation
antigens
Antigens
Interleukin-4
lungs
Allergies
Bronchoalveolar Lavage Fluid
anti-inflammatory agents
metaplasia
eosinophilia
alum
Oncology
Fluids
T-cells
goblet cells
Macrophages
immunotherapy

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Yang, X., Zhu, J., Tung, C. Y., Gardiner, G., Wang, Q., Chang, H. C., & Zhou, B. (2015). Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs. PLoS One, 10(2), [e0115330]. https://doi.org/10.1371/journal.pone.0115330

Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs. / Yang, Xiaowei; Zhu, Jingjing; Tung, Chun Yu; Gardiner, Gail; Wang, Qun; Chang, Hua Chen; Zhou, Baohua.

In: PLoS One, Vol. 10, No. 2, e0115330, 03.02.2015.

Research output: Contribution to journalArticle

Yang X, Zhu J, Tung CY, Gardiner G, Wang Q, Chang HC et al. Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs. PLoS One. 2015 Feb 3;10(2). e0115330. https://doi.org/10.1371/journal.pone.0115330
Yang, Xiaowei ; Zhu, Jingjing ; Tung, Chun Yu ; Gardiner, Gail ; Wang, Qun ; Chang, Hua Chen ; Zhou, Baohua. / Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs. In: PLoS One. 2015 ; Vol. 10, No. 2.
@article{fe34804fce65427abb0039d19f5ae5d0,
title = "Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs",
abstract = "Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and mediator production in macrophages. In this study we demonstrate that lunasin can effectively suppress allergic airway inflammation in two murine models of asthma. In an OVA +Alum sensitization model, intranasal lunasin treatment at the time of OVA challenges significantly reduced total cells counts in bronchoalveolar lavage (BAL) fluid and eosinophilia, peribronchiolar inflammatory infiltration, goblet cell metaplasia and airway IL-4 production. In an OVA+LPS intranasal sensitization model, lunasin treatment either at the time of sensitization or challenge has similar effects in suppress allergic airway inflammation including significantly reduced total cell and eosinophil counts in BAL fluid, inflammatory gene Fizz1 expression in the lung, and IL-4 production by OVA re-stimulated cells from mediastinal lymph nodes. We further show that intranasal instillation of OVA+lunasin significantly increases OVA-specific regulatory T cell (Treg) accumulation in the lung comparing to OVA only treatment. Taken together, our results suggest lunasin as an anti-inflammatory agent can be potentially used in asthma therapy or as an adjuvant to enhance the induction of antigen-specific Tregs and thus boost the efficacy of allergy immunotherapy.",
author = "Xiaowei Yang and Jingjing Zhu and Tung, {Chun Yu} and Gail Gardiner and Qun Wang and Chang, {Hua Chen} and Baohua Zhou",
year = "2015",
month = "2",
day = "3",
doi = "10.1371/journal.pone.0115330",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs

AU - Yang, Xiaowei

AU - Zhu, Jingjing

AU - Tung, Chun Yu

AU - Gardiner, Gail

AU - Wang, Qun

AU - Chang, Hua Chen

AU - Zhou, Baohua

PY - 2015/2/3

Y1 - 2015/2/3

N2 - Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and mediator production in macrophages. In this study we demonstrate that lunasin can effectively suppress allergic airway inflammation in two murine models of asthma. In an OVA +Alum sensitization model, intranasal lunasin treatment at the time of OVA challenges significantly reduced total cells counts in bronchoalveolar lavage (BAL) fluid and eosinophilia, peribronchiolar inflammatory infiltration, goblet cell metaplasia and airway IL-4 production. In an OVA+LPS intranasal sensitization model, lunasin treatment either at the time of sensitization or challenge has similar effects in suppress allergic airway inflammation including significantly reduced total cell and eosinophil counts in BAL fluid, inflammatory gene Fizz1 expression in the lung, and IL-4 production by OVA re-stimulated cells from mediastinal lymph nodes. We further show that intranasal instillation of OVA+lunasin significantly increases OVA-specific regulatory T cell (Treg) accumulation in the lung comparing to OVA only treatment. Taken together, our results suggest lunasin as an anti-inflammatory agent can be potentially used in asthma therapy or as an adjuvant to enhance the induction of antigen-specific Tregs and thus boost the efficacy of allergy immunotherapy.

AB - Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and mediator production in macrophages. In this study we demonstrate that lunasin can effectively suppress allergic airway inflammation in two murine models of asthma. In an OVA +Alum sensitization model, intranasal lunasin treatment at the time of OVA challenges significantly reduced total cells counts in bronchoalveolar lavage (BAL) fluid and eosinophilia, peribronchiolar inflammatory infiltration, goblet cell metaplasia and airway IL-4 production. In an OVA+LPS intranasal sensitization model, lunasin treatment either at the time of sensitization or challenge has similar effects in suppress allergic airway inflammation including significantly reduced total cell and eosinophil counts in BAL fluid, inflammatory gene Fizz1 expression in the lung, and IL-4 production by OVA re-stimulated cells from mediastinal lymph nodes. We further show that intranasal instillation of OVA+lunasin significantly increases OVA-specific regulatory T cell (Treg) accumulation in the lung comparing to OVA only treatment. Taken together, our results suggest lunasin as an anti-inflammatory agent can be potentially used in asthma therapy or as an adjuvant to enhance the induction of antigen-specific Tregs and thus boost the efficacy of allergy immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84922373481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922373481&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0115330

DO - 10.1371/journal.pone.0115330

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0115330

ER -